Assessing the diagnostic value of a potential screening tool for detecting early interstitial lung disease at the onset of inflammatory rheumatic diseases

Table 3 Pulmonary function tests, chest X-ray, HRCT, and origin of pathologies in HRCT, differentiated regarding the ILD group and non-ILD group

Variable	ILD group, number (%)	Non-ILD group, number (%)	Difference
Number	63 (50.0%)	63 (50.0%)
PFT	61 (96.8%)	61 (96.8%)	χ²(1) = 0.000,*P = 1.000*
Median ± SD
DLCO	59.4 ± 19.6%	79.9 ± 18.3%	t(118) = 5.91,*P < 0.001*
TLC	84.4 ± 19.8%	98.5 ± 12.9%	t(95) = 4.47,*P < 0.001*
FVC	82.3 ± 21.3%	92.6 ± 17.9%	t(118) = 2.89,*P = 0.005*
FEV₁	82.0 ± 23.4%	92.2 ± 16.6%	t(104) = 2.78,*P = 0.007*
TLCO	75.0 ± 19.6%	88.1 ± 17.3%	t(116) = 3.84,*P < 0.001*
Chest X-ray	53 (84.1%)	53 (84.1%)	χ²(1) = 0.000,*P = 1.000*
HRCT	63 (100.0%)	38 (60.3%)	χ²(1) = 43.955,*P < 0.001*
Origin of the pathologies in HRCT
ILD in IRD	63 (100.0%)	0 (0.0%)	χ²(4) = 80.000,*P < 0.001*
Respiratory bronchiolitis ILD	0 (0.0%)	7 (11.1%)
Post-inflammatory change	0 (0.0%)	6 (9.5%)
Other lung diseases	0 (0.0%)	2 (3.2%)

DLCO Diffusing capacity for carbon monoxide, FEV₁ Forced expiratory volume in 1 s, FVC Forced vital capacity, HRCT High-resolution computed tomography, LR Likelihood ratio, PFT Pulmonary function tests, TLC Total lung capacity, TLCO Transfer factor of the lung for carbon monoxide

ISSN: 1478-6362